The Biostatistics Shared Resource Facility (BSRF) is a Markey Cancer Center (MCC)-managed resource providing comprehensive and centralized support that is readily accessible to cancer center investigators.
The specific aims of the BSRF encompass support during study planning and study conduct and at the final stage of each project. In order to achieve these aims, our services are categorized broadly into: 1) study planning, power, and sample size calculations for grant applications, clinical trials, population-based studies, and preclinical experiments;2) statistical analyses, including interim and final analysis for the entire spectrum of cancer research studies;3) statistical programming for data quality control and data processing;and 4) mentoring, teaching, and general consultation to MCC investigators. We also collaborate closely with MCC's Clinical Research and Data Management SRF, Cancer Research Informatics SRF, and other MCC shared facilities. The shared resource personnel include six faculty statisticians, two master's-level statisticians, and a faculty bioinformatician. Collectively, they have extensive cancer-specific experience, expertise, and ongoing collaborations with investigators involved in studies ranging from laboratory, in vitro, in vivo studies in mouse models of cancer, translational, and bioinformatics studies in clinical samples, clinical trials, and population-based intervention studies. BSRF personnel are highly integrated with investigators across all research programs and interact closely with other SRFs at MCC to ensure comprehensive and seamless support. With personnel who are well-versed in all aspects of the biostatistical needs of MCC investigators, the dedicated BSRF team adds significant value to the conduct of research at the MCC.
The Biostatistics Shared Resource Facility (BSRF) plays a key collaborative role in providing scientific and statistical input across the entire spectrum of cancer research being performed at the MCC. This SRF has demonstrated significant impact in the conduct of science at MCC, as evidenced by participating as co-investigators in grant applications, providing critical input in clinical trial development and trial conduct, and co-authoring with investigators in all research programs of the MCC.
|Gedaly, Roberto; De Stefano, Felice; Turcios, Lilia et al. (2018) mTOR Inhibitor Everolimus in Regulatory T cell Expansion for Clinical Application in Transplantation. Transplantation :|
|Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89|
|Wang, Qingding; Zhou, Yuning; Rychahou, Piotr et al. (2018) Deptor Is a Novel Target of Wnt/?-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth. Cancer Res 78:3163-3175|
|Rychahou, Piotr; Bae, Younsoo; Reichel, Derek et al. (2018) Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles. J Control Release 275:85-91|
|Kosmac, Kate; Peck, Bailey D; Walton, R Grace et al. (2018) Immunohistochemical Identification of Human Skeletal Muscle Macrophages. Bio Protoc 8:|
|Frohman, Heather A; Rychahou, Piotr G; Li, Jing et al. (2018) Development of murine bariatric surgery models: lessons learned. J Surg Res 229:302-310|
|Chaiswing, Luksana; St Clair, William H; St Clair, Daret K (2018) Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer. Antioxid Redox Signal 29:1237-1272|
|Chauhan, Aman; Farooqui, Zainab; Murray, Le Aundra et al. (2018) Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary. J Oncol 2018:3519247|
|Zhang, Xiaofei; Zhang, Yi; Han, Erik Y et al. (2018) Classification of Whole Mammogram and Tomosynthesis Images Using Deep Convolutional Neural Networks. IEEE Trans Nanobioscience 17:237-242|
|Li, Jing; Song, Jun; Li, Xian et al. (2018) FFAR4 Is Involved in Regulation of Neurotensin Release From Neuroendocrine Cells and Male C57BL/6 Mice. Endocrinology 159:2939-2952|
Showing the most recent 10 out of 359 publications